Pharmaceutical company to pay La. more than $1 million in settlement
BATON ROUGE - The Attorney General's Office says a settlement has been reached with drugmaker Amgen Inc. to resolve claims the company violated Louisiana consumer protection laws in the marketing of its drugs Enbrel and Aranesp.
The settlement is part of an agreement between Amgen and 49 states that requires the company to alter its marketing and promotional practices related to the drugs. The pharmaceutical company will pay the state more than $1 million as part of the settlement.
Amgen is accused of illegally promoting Aranesp and Enbrel for uses not approved by the FDA. Future marketing and promotional material from the company must not make false, misleading or deceptive claims about Enbrel or any drug in the same class as Aranesp, according to the Attorney General's Office.
Aranesp is used to treat certain types of anemia by stimulating bone marrow to produce red blood cells. Enbrel is sued to treat several conditions, including plaque psoriasis.
Amgen is expected to pay a total of $71 million to the 49 states involved in the settlement.